Clinical Handbook of Psychotropic Drugs, 25th Edition
By Ric M. Procyshyn, Kalyna Z. Bezchlibnyk-Butler, David D. Kim
The Clinical Handbook of Psychotropic Drugs is a comprehensive and essential reference tool for mental health professionals. Written by Ric M. Procyshyn, Kalyna Z. Bezchlibnyk-Butler, and David D. Kim, this handbook provides quick and accurate information on psychotropic drugs for adults.
One of the standout features of this handbook is its comparison charts, which greatly aid in the decision-making process. These charts provide a clear overview of treatment options, including dosages, side effects, pharmacokinetics, and interactions. They are easy to read and understand, making it simple to compare different medications and choose the most appropriate one for each patient.
In addition to the comparison charts, the Clinical Handbook of Psychotropic Drugs is packed with other useful features. The information is presented in a concise and easily digestible format, with bulleted points providing key details on each class of medication. Each class of drug is thoroughly covered, including on-label and off-label indications, side effects, interactions, pharmacodynamics, precautions in different populations (such as the young, elderly, and pregnant), nursing implications, and much more. This comprehensive coverage ensures that you have all the information you need for each medication class.
The handbook also includes summary charts that highlight potential interactions and side effects, making it quick and convenient to find the information you need. With instantly recognizable icons and full-color throughout, the handbook is visually appealing and allows for easy navigation.
A unique feature of the Clinical Handbook of Psychotropic Drugs is the availability of printable patient information sheets. These sheets provide clear and concise information about each medication, making it easier for patients to understand their prescribed treatment options. The sheets can be downloaded as printable PDF files, allowing you to provide your patients with easy-to-read materials that they can reference at home.
Whether you are a psychiatrist, psychologist, physician, pharmacist, nurse, or other mental health professional, the Clinical Handbook of Psychotropic Drugs is an indispensable tool. It provides independent, unbiased, and up-to-date information on psychotropic medications, making it an essential reference for anyone working in the field.
In this latest edition of the handbook, several updates and additions have been made to ensure that the information remains current and relevant. For example, the antidepressants chapter now includes a section on a new combination product called Auvelity extended-release tablets, which combines an NMDA receptor antagonist with a CYP2D6 inhibitor. The antipsychotics chapter has been revised to include updated monitoring tables for clozapine, including requirements for patients with or without non-benign ethnic neutropenia. The mood stabilizers sections have also been extensively revised, particularly the sections on lithium and anticonvulsants. The dementia chapter now includes information on Lecanemab (Leqembi), a new FDA-approved treatment for Alzheimer’s disease. The treatment of substance use disorders chapter has been updated to include a rapid micro-induction method for buprenorphine dosing, allowing treatment to start without waiting for the patient to be in withdrawal. The chapters on unapproved treatments of psychiatric disorders, natural health products, and pharmacogenetics have all been extensively revised to provide the most current information. Additionally, new formulations and trade names have been added to reflect the latest developments in the field, such as Invega Hafyera (paliperidone long-acting 6-monthly IM injection), Subutex (buprenorphine sublingual tablets), and Quviviq (daridorexant tablets).
The Clinical Handbook of Psychotropic Drugs is a must-have resource for anyone in the mental health field who needs access to accurate, up-to-date, and comprehensive information on psychotropic medications. With its user-friendly format, clear charts and tables, and downloadable patient information sheets, this handbook will greatly enhance your practice and ensure that you can provide the best possible care to your patients.
Order your copy of the Clinical Handbook of Psychotropic Drugs today and join the many mental health professionals who rely on this trusted resource to support their practice.
Product Details
- Publisher: HOGRE; 25th edition (June 30, 2023)
- Language: English
- Spiral-bound: 480 pages
- ISBN-10: 0889376328
- ISBN-13: 978-0889376328
Product Details
- – Accurate and up-to-date
- – Comparison charts help decision-making
- – Icons and full color
- – Available in print and online
- – Downloadable patient info sheets
- • Independent, unbiased, up-to-date
- • Packed with unique, easy-to-read comparison charts and tables (dosages, side effects, pharmacokinetics, interactions…) for a quick overview of treatment options
- • Succinct, bulleted information on all classes of medication: on- and off-label indications, side effects, interactions, pharmacodynamics, precautions in the young, the elderly, and pregnancy, nursing implications, and much more – all you need to know for each class of drug
- • Potential interactions and side effects summarized in comparison charts
- • With instantly recognizable icons and in full color throughout, allowing you to find at a glance all the information you seek
- • Clearly written patient information sheets available for download as printable PDF files
- • Antidepressants chapter includes a new section on the NMDA receptor antagonist/CYP2D6 inhibitor combination product (dextromethorphan/bupropion; Auvelity extended-release tablets)
- • Antipsychotics updates include revised Clozapine monitoring tables which now also contain monitoring requirements for patients with or without non-benign ethnic neutropenia
- • Mood Stabilisers sections on Lithium and Anticonvulsants extensively revised
- • Dementia chapter includes a new section on Lecanemab (Leqembi), a fast-track FDA approved treatment for Alzheimer’s disease
- • Treatment of Substance Use Disorders includes revisions to Buprenorphine dosing section to include a rapid micro-induction method (Bernese method) that allows treatment to start without waiting for patient to be in withdrawal
- • Unapproved treatments of Psychiatric Disorders, Natural Health Products, and Pharmacogenetic chapters all substantially revised
- • New formulations and trade names include: Invega Hafyera (paliperidone long-acting 6-monthly IM injection), Subutex (buprenorphine sublingual tablets), Quviviq (daridorexant tablets)
- Publisher : HOGRE; 25th edition (June 30, 2023)
- Language : English
- Spiral-bound : 480 pages
- ISBN-10 : 0889376328
- ISBN-13 : 978-0889376328